Athletes with exercise induced fatigue have abnormally short muscle DNA telomeres

Telomeres » Institutional Study » Athletes with exercise induced fatigue have abnormally short muscle DNA telomeres

April 28, 2017 | Amy | 1 Comment

Peer-Reviewed Scientific Journal:
Medicine & Science in Sports & Exercise

Size of study:
13 subjects with FAMS, 13 healthy controls

Summary
This study found that endurance athletes diagnosed with fatigued athlete myopathic syndrome had shorter telomeres in their muscles cells than controls. This study is intriguing because it hints at the long term implications of intense training over long periods of time. Intense exercise incurs high oxidative stress loads and the repetitive injury to muscle requires high levels of cellular replication – both of these conditions are primary contributors to telomere attrition.

Link to study

SEE THE FULL STUDY

One comment on “Athletes with exercise induced fatigue have abnormally short muscle DNA telomeres”

Bob says:

August 2, 2017 at 1:20 am

Bi polarity in its manic stage over a lifetime may have the same result

Reply

Leave a Reply Cancel reply

The TeloYears test is not intended for screening, diagnosing, treating or preventing diseases or medical conditions. The TeloYears genetic test may indicate the possibility of identifying a rare telomere syndrome associated with extremely shorter or longer average telomere length (ATL). In these rare cases, further testing and consultation with a doctor to rule in or rule out a telomere syndrome is recommended. The test is available for individuals between the ages of 20 to 80 within the United States, except for the states of Maryland and New York. The information provided by the TeloYears test should not be used to replace medically appropriate screening tests recommended based upon actual age or other risk factors, nor should the information be used to make decisions about diagnosis or treatment of diseases or medical conditions. The Telomere Diagnostics lab is regulated under the Clinical Laboratory improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical testing. The performance characteristics of this test were determined by Telomere Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration.